Takeda and Molecular Templates will work to develop targeted engineered toxin bodies for multiple myeloma. Celgene decides against optioning OncoMed’s navicixizumab for ovarian cancer, while CRISPR and ViaCyte team up on type 1 diabetes.

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Focusing on an idea that many autoimmune diseases are caused by proteins from viral genes that are now embedded in human DNA, Swiss biotech GeNeuro is using the idea to develop therapeutics.

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.